论文部分内容阅读
伊马替尼对慢性粒细胞白血病的分子靶向性治疗获得了极大的成功,病人的生存时间延长,生活质量接近正常人。由于伊马替尼可能导致畸形,通常建议患者服药治疗期间避免妊娠。近年来,伊马替尼治疗的患者中选择妊娠及合并妊娠、成功分娩的个案多有报告,但尚无流行病学的大样本研究结果支持伊马替尼治疗的患者可以选择生育,对伊马替尼治疗影响生育和生殖的研究也仅停留于动物实验。本文就伊马替尼对慢性粒细胞白血病患者生育和生殖的影响作一综述。
Imatinib has achieved tremendous success in the molecular targeted therapy of chronic myeloid leukemia, with prolonged patient survival and quality of life approaching normal. As imatinib may cause deformities, it is usually advisable to avoid pregnancy during medication. In recent years, Imatinib treatment of patients in the choice of pregnancy and pregnancy, the successful delivery of a large number of cases, but there is no epidemiological large sample of studies to support the treatment of patients with imatinib can choose to have children, the Iraqi The study of the effect of treatment with mastitis on fertility and reproduction also lasted only in animal experiments. This article reviews the impact of imatinib on the fertility and reproduction of patients with chronic myeloid leukemia.